 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C27H34N4O5 |
| Molar mass | 494.6 g/mol g·mol−1 |
Retosiban (GSK-221,149-A) [1] is an oral drug which acts as a selective, sub-nanomolar (Ki=0.65 nM) oxytocin receptor antagonist with >1400-fold selectivity [2] over the related vasopressin receptors and is being developed by GlaxoSmithKline for the treatment of preterm labour.[3][4]
References edit
- ^ Liddle J, Allen MJ, Borthwick AD, Brooks DP, Davies DE, Edwards RM, Exall AM, Hamlett C, Irving WR, Mason, AM, McCafferty GP, Nerozzi F, Peace S, Philp J, Pollard D, Pullen MA, Shabbir SS, Sollis SL, Westfall TD, Woollard PM, Wu C, Hickey DM (2008). "The discovery of GSK221149A: A potent and selective oxytocin antagonist". Bioorganic & Medicinal Chemistry Letters. 18 (1): 90–94. doi:10.1016/j.bmcl.2007.11.008. PMID 18032036.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ McCafferty GP, Pullen MA, Wu C, Edwards RM, Allen M.J, Woollard PM, Borthwick AD, Liddle J, Hickey DM, Brooks DP, Westfall TD (2007). "Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat". American Journal of Physiology - Regulatory, Integrative and Comparative Physiology. 293 (1): R299–R305. doi:10.1152/ajpregu.00057.2007. PMID 17395790.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ USAN Council (2007). "Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF).
- ^ Borthwick AD, Liddle J (2011). "The Design of Orally Bioavailable 2,5-Diketopiperazine Oxytocin Antagonists: From Concept to Clinical Candidate for Premature Labour". Medicinal Research Reviews. 31 (4): 576–604. doi:10.1021/jm901812z. PMID 20027670.
{{cite journal}}: Unknown parameter|month=ignored (help)